

Synergism of Prostaglandin E₂ and Nitric Oxide on Human Osteoblast Proliferation Induced by Hydroxyapatite

Erwan Sugiatno¹, Endang Herminajeng², Wihaskoro Sosroseno³

ABSTRACT

Aim: To assess whether osteoblast proliferation induced by hydroxyapatite (Ha) may be regulated by prostaglandin E₂ (PGE₂) and nitric oxide (NO) in a synergic fashion.

Materials and methods: Human osteoblasts (HOS cell line) were cultured onto Ha with or without nimesulide, a cyclooxygenase-2 (COX-2), and/or L-NIO, an endothelial nitric oxide synthase (eNOS) inhibitor. The cells pretreated with nimesulide and/or L-NIO were cultured onto Ha added with PGE₂ and/or S-nitroso acetyl penicillamine (SNAP), a NO donor. The Ha-plated cell cultures were also added with anti-PGE₂ and/or carboxy PTIO, a NO scavenger. The cell proliferation was assessed colorimetrically from the 3-day cultures. The levels of PGE₂ and NO were determined from the culture supernatants.

Results: Hydroxyapatite-induced cell proliferation was partially inhibited by nimesulide or L-NIO but fully by both inhibitors. The production of PGE₂ from the same cell cultures was inhibited fully by nimesulide but partially by L-NIO. In contrast, NO production was inhibited only by L-NIO. Partial suppression of Ha-stimulated cell proliferation by nimesulide or L-NIO was abolished by PGE₂ or NO, respectively. The combination of PGE₂ and NO donor could abrogate fully nimesulide—but partially L-NIO-mediated suppression of Ha-induced cell proliferation. Anti-PGE₂ or carboxy PTIO partially inhibited but combination of both scavengers fully suppressed the Ha-induced cell proliferation.

Conclusion: Osteoblast proliferation induced by Ha may be regulated by a synergic function of PGE₂ and NO in an autocrine fashion.

Clinical significance: The successful or failing Ha-based dental implantation may be determined by the synergic regulatory functions of the host PGE₂ and NO at the implanted sites.

Keywords: Hydroxyapatite, Nitric oxide, Osteoblasts, PGE₂, Proliferation.

World Journal of Dentistry (2019): 10.5005/jp-journals-10015-1678

INTRODUCTION

The crucial roles of nitric oxide (NO) and prostaglandin E₂ (PGE₂) in the regulation of bone remodeling have been well studied. Prostaglandin E₂ is a prostanoid synthesized by the action of cyclooxygenases (COX-1 and COX-2) on arachidonic acid,¹ and is a potent regulator of osteoclast and osteoblast differentiation and proliferation.² Interestingly, the most recent report showed that the regulatory role of PGE₂ on bone formation is via its role on sensory nerve which in turn inhibits sympathetic activity and, hence, promotes osteogenesis.³ Nitric oxide is a gaseous molecule generated from nitric oxide synthases (NOS)—catalyzed L-arginine metabolism and is a crucial molecule on bone remodeling.⁴ For example, NO was reported to directly stimulate osteoblast proliferation.⁵ Interestingly, NO was able to modulate the COX-2-mediated PGE₂ production by cytokine-stimulated rat osteoblasts,⁶ fluid shear stress-stimulated rat preosteoblasts,⁷ and ascorbic acid-induced mouse osteoblast differentiation,⁸ suggesting the existence of the NO–PGE₂ crosstalk during bone formation in physiological or pathological condition.

Hydroxyapatite (Ha) is commonly used for orthopedic and dental implants because of its potent osteoconductive properties.⁹ Binding between osteoblast-derived integrin molecules and its ligand expressed by Ha covering protein layer results in the cells releasing numerous mediators, such as osteopontin, PGE₂, and transforming growth factor-β (TGF-β) which involve in bone remodeling.^{10–14} Previous reports indicated that upon binding between integrin αV-expressing human osteoblasts and Ha, cell proliferation, and the production of endothelial NOS (eNOS)-catalyzed NO and COX-2-mediated PGE₂ are observed.^{15,16} Furthermore, NO-regulated Ha-plated osteoblast proliferation by amplifying cell proliferation,

¹Department of Prosthodontic, Faculty of Dentistry, Gadjah Mada University, Yogyakarta, Indonesia

^{2,3}Oral Biology Unit, Faculty of Dentistry, AIMST University, Bedong, Kedah, Malaysia

Corresponding Author: Wihaskoro Sosroseno, Oral Biology Unit, Faculty of Dentistry, AIMST University, Bedong, Kedah, Malaysia, Phone: +60 44298 000, e-mail: wihassosroseno@gmail.com

How to cite this article: Sugiatno E, Herminajeng E, Sosroseno W. Synergism of Prostaglandin E₂ and Nitric Oxide on Human Osteoblast Proliferation Induced by Hydroxyapatite. *World J Dent* 2019;10(6):449–453.

Source of support: The Fundamental Research Grant Scheme from the Malaysian Government

Conflict of interest: None

PGE₂ production, and cAMP-PKA signal transduction pathway.^{16–18} Interestingly, inhibition of eNOS activity was associated with suppression of PGE₂ production by Ha-plated osteoblasts,¹⁸ suggesting a possible regulatory link between NO and PGE₂ in the human osteoblast proliferation stimulated with Ha. Therefore, the aim of the study was to test whether PGE₂ and NO may synergically regulate the proliferation of human osteoblasts induced by Ha.

MATERIALS AND METHODS

All materials were purchased from Sigma (St. Louis, MO, USA), unless otherwise stated. Sintered and sterilized Ha (9% porosity) were provided by the School of Materials and Mineral Resource Engineering, USM, Malaysia.¹⁵ Human osteoblasts (HOS cell line) was obtained from American Type Culture Collection (Rockville, MD, USA).

The culture medium containing Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum and 1% penicillin–streptomycin were used to culture the cells. One million cells in 1 mL of the culture medium containing 100 µM of nimesulide, a COX-2 inhibitor, and/or 100 µM of L-NIO, an eNOS inhibitor, were incubated for 30 minutes at room temperature as previously described.^{15,18} Two hundred thousand cells in 200 µL of culture medium were cultured onto Ha with or without 10 µM of PGE₂ and/or 20 µM of SNAP, a NO donor, in the 96-well plates (Corning, NY, USA). Furthermore, 2 × 10⁵ cells in 200 µL of cell suspension were cultured onto Ha and then, 100 pg of polyclonal anti-PGE₂ and/or 100 µM of 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (carboxy PTIO), a NO scavenger, were added.¹⁵ The cells cultured with or without Ha were served as the positive or negative control, respectively. All cultures prepared in triplicate were then incubated for 3 days at 37°C in a humidified atmosphere and 5% CO₂.

The cell proliferation was determined as previously documented.¹⁵ Briefly, the cells were treated with 100 µL of 20% methanol for 10 minutes followed by 100 µL of 0.5% crystal violet for 5 minutes. After washing, the cells were treated with 100 µL of 0.5% crystal violet for 5 minutes for releasing the dye. The solution was read spectrophotometrically at 540 nm (Biotek-Instrument, Inc., Winooski, Vt). After subtracting from the reading of medium only, the results were expressed as absorbance unit.

The end product of NO, i.e., nitrite, was determined by the Griess reagent containing 1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride in 2.5% phosphoric acid.¹⁵ Equal volume (100 µL) of culture supernatant and the reagent were mixed and then read spectrophotometrically at 540 nm (Biotek-Instrument, Inc., Winooski, Vt). Sodium nitrite was used to prepare a standard curve.

The levels of culture supernatant PGE₂ was assessed by using a commercial kit (Cayman Chemical Co., Ann Arbor, MI, USA). Statistically, one-way analysis of variance followed by Fischer's least square differences (SPPS, Chicago, Ill, USA) was used to analyze the data.

RESULTS

The Effect of Nimesulide and/or L-NIO

Hydroxyapatite did induce proliferation of osteoblasts as compared with the negative control ($p < 0.05$), as shown in Table 1. Similarly, PGE₂ and NO were simultaneously produced by cells induced by Ha ($p < 0.05$). Nimesulide or L-NIO did cause Ha-stimulated cell proliferation lower than the positive but higher than the negative control ($p < 0.05$). Interestingly, while nimesulide inhibited PGE₂ but not NO production ($p < 0.05$), L-NIO suppressed both NO

and PGE₂ by Ha-stimulated cells ($p < 0.05$). The Ha-induced cell proliferation and production of both PGE₂ and NO were abolished by combination of nimesulide and L-NIO ($p < 0.05$).

Furthermore, nimesulide significantly decreased cell proliferation induced by Ha but exogenous PGE₂ or NO partially abolished this nimesulide-mediated suppression of cell proliferation ($p < 0.05$) (Fig. 1). Interestingly, the inhibitory effect of nimesulide on Ha-induced cell proliferation was abrogated by combination of exogenous PGE₂ and NO as compared with the positive control ($p < 0.05$). Moreover, an eNOS inhibitor (L-NIO) in the Ha-plated cell cultures led to the cell proliferation lower than the positive control ($p < 0.05$) (Fig. 2). The suppressive L-NIO on cell proliferation could be partially overcome by exogenous PGE₂ ($p < 0.05$) but completely abrogated by exogenous NO ($p < 0.05$). Interestingly, when the cells were pretreated with L-NIO, added with combination of PGE₂ and NO donor, and then cultured onto Ha, the cell proliferation was lower than the positive control but still higher than the negative control ($p < 0.05$).

The effect of simultaneous COX-2 and eNOS inhibition by their respective inhibitor on Ha-induced cell proliferation was examined and the results are depicted in Figure 3. The proliferation of cells induced by Ha was suppressed by combination of nimesulide and L-NIO as compared with both positive and negative control ($p < 0.05$). The suppressive effect of these inhibitors on the cell proliferation induced by Ha was partially abrogated by either exogenous PGE₂ or NO but completely abolished by combination of exogenous PGE₂ and NO ($p < 0.05$).

Effect of Anti-PGE₂ and/or Carboxy PTIO

Anti-PGE₂ antibody or carboxy PTIO induced lower osteoblast proliferation stimulated by Ha than the positive but higher than the negative control ($p < 0.05$) (Fig. 4). The proliferation of cells treated with the combination of anti-PGE₂ antibody and carboxy PTIO and then cultured onto Ha was lower than that of the positive control ($p < 0.05$) and was, in fact, comparable with that of the negative control ($p > 0.05$).

DISCUSSION

The present study showing the cell proliferation and both PGE₂ and NO production by osteoblasts induced by Ha are not unexpected and have been reported.^{13,15,18} These results are also supported by the fact that ultrasound-induced osteoblasts produce PGE₂ and NO.¹⁹ Furthermore, when the production of PGE₂ and NO was inhibited by cyclooxygenase-2 and eNOS inhibitor respectively, the cell proliferation induced by Ha was partially decreased, suggesting that PGE₂ or NO alone may individually act as a partial regulator

Table 1: Effect of COX-2 and/or eNOS inhibitor on the cell proliferation and both prostaglandin E₂ and nitric oxide production by hydroxyapatite-stimulated osteoblasts

Cultures	Cell proliferation (absorbance unit) (mean + SD)	PGE ₂ (pg/mL) (mean + SD)	Nitrite (µM) (mean + SD)
Cells	0.094 + 0.002	80.667 + 2.867	5.233 + 0.499
Cells + Ha	0.261 + 0.005 [#]	141.667 + 3.858 [#]	14.483 + 1.375 [#]
Cells + Ha + L-NIO	0.134 + 0.009 ^{#*}	98.333 + 6.599 ^{#*}	0.950 + 0.043 ^{#*}
Cells + Ha + nimesulide	0.140 + 0.007 ^{#*}	1.133 + 0.275 ^{#*}	14.543 + 0.903 [#]
Cells + Ha + nimesulide + L-NIO	0.082 + 0.007 [*]	1.197 + 0.200 ^{#*}	0.933 + 0.074 ^{#*}

Note: Ha, hydroxyapatite; nimesulide, cyclooxygenase (COX)-2 inhibitor (100 µM); L-NIO, an endothelial nitric oxide synthase (eNOS) inhibitor (100 µM)

[#]Significant difference to the negative control (cells only) at $p < 0.05$

^{*}Significant difference to the positive control (cells + Ha) at $p < 0.05$




Fig. 1: Effect of exogenous prostaglandin E₂ and/or nitric oxide on the proliferation of human osteoblasts treated with a cyclooxygenase (COX)-2 inhibitor (nimesulide) and stimulated with hydroxyapatite




Fig. 2: Effect of exogenous prostaglandin E₂ and/or nitric oxide on the proliferation of human osteoblasts treated with an endothelial nitric oxide synthase inhibitor (L-NIO) and stimulated with hydroxyapatite

on the human osteoblast proliferation stimulated with Ha. This notion is particularly evidenced by the fact that when complete inhibition of Ha-induced osteoblast proliferation could only be achieved by concurrent inhibition of COX-2 and eNOS activity in the present study, indicating requirement of both PGE₂ and NO on the proliferation of human osteoblasts stimulated with hydroxyapatite. The explanation on these results is not well understood. Several studies indicated a possible regulatory link of PGE₂ and NO released by stimulated osteoblasts since activated osteoblasts produced NO which in turn modulates the secretion of COX-2-mediated PGE₂ and alters osteoblast functions.⁶⁻⁸ Hence, a possible link between NO and PGE₂ in the regulation of human osteoblast proliferation induced by Ha in the present study should not be ruled out.

That the suppressive effect of COX-2 proliferation of human osteoblasts induced by Ha could be abrogated fully by PGE₂ but partially by NO donor may validate that PGE₂ alone may only partially regulate the Ha-induced cell proliferation. Similarly, NO seems also to partially involve in the regulation of Ha-induced cell

proliferation, since NO donor but not PGE₂ recover the suppressive effect of eNOS inhibitor on the cell proliferation. These results could be supported by the fact that PGE₂ and NO are individually potent promoter on implant material-induced osteoblast proliferation.^{17,20} It should be noted, furthermore, that after adding both exogenous PGE₂ and NO into the Ha-plated cell cultures, the proliferation of cells preincubated with COX-2 inhibitor was accelerated but that preincubated with eNOS inhibitor was inhibited. These results may imply that combination of low PGE₂ and high NO levels may accelerate the Ha-induced cell proliferation. Conversely, combination of high PGE₂ and low NO may inhibit the Ha-induced cell proliferation. The reciprocal levels of PGE₂ and NO in the surrounding tissues of implanted site could also be found in the experimental aseptic implant loosening in sheep.²¹ In this study, the levels of NO in the stable implants were higher than those of PGE₂ but reversed profile occurred in the failed implants. The exact mechanism(s) to explain these phenomena remains unclear, however. NO was found to upregulate the cell proliferation and




Fig. 3: Effect of exogenous prostaglandin E₂ and/or nitric oxide on the proliferation of human osteoblasts treated with the combination of nimesulide and L-NIO and stimulated with hydroxyapatite




Fig. 4: Effect of anti-prostaglandin E₂ and/or a nitric oxide scavenger (carboxy PTIO) on the proliferation of human osteoblasts stimulated with hydroxyapatite

PGE₂ production by Ha-stimulated human osteoblasts.¹⁵⁻¹⁷ Previous reports demonstrating that nitric oxide enhances the production of PGE₂ by inflammatory cytokine-stimulated osteoblasts²² and that increased PGE₂ levels seem to be responsible for the inhibition of Ha-induced osteoblast functions¹³ may be in accordance with the results of the present study.

When both COX-2 and eNOS were simultaneously inhibited, the proliferation of osteoblasts induced by Ha could only be fully recovered by combination of exogenous NO and PGE₂ but neither one of them, validating the view that the proliferation of human osteoblasts induced by Ha may require simultaneous action of both endogenous PGE₂ and NO. Indeed, that combination of anti-PGE₂ antibody and carboxy PTIO inhibited osteoblast proliferation induced by Ha clearly indicates that PGE₂ and NO do play a synergic role in Ha-induced human osteoblast proliferation in an autocrine fashion. The NO-PGE₂ crosstalk via peroxynitrite-mediated pathway or S-nitrosylation of COX enzymes in different types of cells has been well documented²³ and may support the present study.

Alternatively, NO released by Ha-induced osteoblasts may amplify intracellular activation of the cAMP-PKA pathway which may in turn increase PGE₂ production¹⁸ and hence, upregulate the cell proliferation. The fact that increased PGE₂ production was associated with increased the cAMP-PKA pathway which might then upregulate bone remodeling²⁴ may also be in the line of this notion. However, this assumption requires to be further studied.

The clinical implication of the present study in orthopedic and dental implantation with Ha in humans needs to be further studied. Examination on the site of dental implants showed that low levels of PGE₂ and NO in healthy implant are associated with bone formation remodeling but high levels of these mediators are observed in the sites of implant failure.²⁵⁻²⁷ Therefore, one may assume that both PGE₂ and NO released by osteoblasts and other cells at the surrounding implanted materials may regulate the bone remodeling in a synergic fashion and that their combined concentration may determine whether the orthopedic or dental implantation is successful or failed treatment.

CONCLUSION

The proliferation of human osteoblast induced by Ha could be inhibited partially by nimesulide or L-NIO but fully by combination of these inhibitors. In fact, only nimesulide, but not L-NIO-mediated suppression of Ha-stimulated cell proliferation could only be abrogated by combination of PGE₂ and NO. The suppression of Ha-induced cell proliferation due to simultaneous inhibition of COX-2 and eNOS activity could only be abolished by combined PGE₂ and NO but neither one of them. The cell proliferation stimulated with Ha was inhibited partially by anti-PGE₂ antibody or carboxy PTIO alone but fully by combination of both scavengers. Therefore, the present study suggests that human osteoblast proliferation induced by Ha may be regulated by a synergic function of PGE₂ and NO in an autocrine fashion.

CLINICAL SIGNIFICANCE

This *in vitro* study may imply that the successful or failing Ha-based dental implantation may be determined by the synergic regulatory functions of the host PGE₂ and NO at the implanted sites.

ACKNOWLEDGMENT

The authors gratefully acknowledge the School of Material and Mineral Resource Engineering, Universiti Sains Malaysia, for providing Ha.

REFERENCES

- Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E₂-biosynthetic pathway. *Prog Lipid Res* 2004;43(1):3–35. DOI: 10.1016/S0163-7827(03)00037-7.
- Kaneki H, Takasugi I, Fujieda M, et al. Prostaglandin E₂ stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism in the culture of adult rat calvarial osteoblasts. *J Cell Biochem* 1999;73(1):36–48. DOI: 10.1002/(SICI)1097-4644(19990401)73:1<36::AID-JCB5>3.0.CO;2-F.
- Chen H, Hu B, Lv X, et al. Prostaglandin E₂ mediates sensory nerve regulation of bone homeostasis. *Nat Commun* 2019;10(1):181. DOI: 10.1038/s41467-018-08097-7.
- Van't Hof RJ, Ralston SH. Nitric oxide and bone. *Immunology* 2001;103(3):255–261. DOI: 10.1046/j.1365-2567.2001.01261.x.
- Otsuka E, Hirano K, Matsushita S, et al. Effects of nitric oxide from exogenous nitric oxide donors on osteoblastic metabolism. *Eur J Pharmacol* 1998;349(2–3):345–350. DOI: 10.1016/S0014-2999(98)00190-3.
- Hughes FJ, BATTERY LD, HUKKANEN MV, et al. Cytokine-induced prostaglandin E₂ synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and -independent mechanism in rat osteoblasts *in vitro*. *J Biol Chem* 1999;274(3):1776–1782. DOI: 10.1074/jbc.274.3.1776.
- McAllister TN, Du T, Frangos JA. Fluid shear stress stimulates prostaglandin and nitric oxide release in bone marrow-derived preosteoclast-like cells. *Biochem Biophys Res Commun* 2000;270(2):643–648. DOI: 10.1006/bbrc.2000.2467.
- Koyama A, Otsuka E, Inoue A, et al. Nitric oxide accelerates the ascorbic acid-induced osteoblastic differentiation of mouse stromal ST2 cells by stimulating the production of prostaglandin E₂. *Eur J Pharmacol* 2000;391(3):225–231. DOI: 10.1016/S0014-2999(00)00100-X.
- Gotz W, Papageorgiou SN. Molecular, cellular and pharmaceutical aspects of synthetic hydroxyapatite bone substitutes for oral and maxillofacial grafting. *Curr Pharm Biotechnol* 2017;18(1):95–106. DOI: 10.2174/1389201017666161202103218.
- Anselme K. Osteoblast adhesion on biomaterials. *Biomaterials* 2000;21(7):667–681. DOI: 10.1016/S0142-9612(99)00242-2.
- Siebers MC, Ter Grugge PJ, Walboomers XF, et al. Integrins as linker proteins between osteoblasts and bone replacing materials. A critical review. *Biomaterials* 2005;26(2):137–146. DOI: 10.1016/j.biomaterials.2004.02.021.
- Uemura T, Nemoto A, Liu Y-K, et al. Osteopontin involvement in bone remodeling and its effects on *in vivo* osteogenic potential of bone marrow-derived osteoblasts/porous hydroxyapatite construct. *Mater Sci Eng C* 2001;17(1–2):33–36. DOI: 10.1016/S0928-4931(01)00332-0.
- Sun JS, Tsuang YH, Liao CJ, et al. The effects of calcium phosphate particles on the growth of osteoblasts. *J Biomed Mater Res* 1997;37(3):324–334. DOI: 10.1002/(SICI)1097-4636(19971205)37:3<324::AID-JBM3>3.0.CO;2-N.
- Bigi A, Bracci B, Cuisinier F, et al. Human osteoblast response to pulsed laser deposited calcium phosphate coating. *Biomaterials* 2005;26(15):2381–2389. DOI: 10.1016/j.biomaterials.2004.07.057.
- Sosroseno W, Sugiatno E, Samsudin AR, et al. The role of nitric oxide on the proliferation of a human osteoblast cell line (HOS cells) stimulated with hydroxyapatite. *J Oral Implantol* 2008;34(4):196–202. DOI: 10.1563/0.910.1.
- Sugiatno E, Samsudin AR, Ibrahim MF, et al. The effect of nitric oxide on the production of prostaglandin E₂ by hydroxyapatite-stimulated a human osteoblast (HOS) cell line. *Biomed Pharmacother* 2006;60(4):147–151. DOI: 10.1016/j.biopha.2006.02.008.
- Sugiatno E, Samsudin AR, Sosroseno W. Effect of exogenous nitric oxide on the proliferation of a human osteoblast (HOS) cell line induced by hydroxyapatite. *J Appl Biomater Biomech* 2008;7(1):29–33.
- Sosroseno W, Sugiatno E. Cyclic-AMP-dependent proliferation of a human osteoblast cell line (HOS cells) induced by hydroxyapatite: effect of exogenous nitric oxide. *Acta Biomed* 2008;79(2):110–116.
- Reher P, Harris M, Whiteman M, et al. Ultrasound stimulates nitric oxide and prostaglandin E₂ production by human osteoblasts. *Bone* 2002;31(1):236–241. DOI: 10.1016/S8756-3282(02)00789-5.
- Zizzari VL, Marconi GD, De Colli M, et al. *In vitro* behavior of primary human osteoblasts onto microrough titanium surface. *Implant Dent* 2015;24(4):377–383. DOI: 10.1097/ID.0000000000000268.
- El-Warrak AO, Olmstead M, Schneider R, et al. An experimental animal model of aseptic loosening of hip prostheses in sheep to study early biochemical changes at the interface membrane. *BMC Musculoskelet Disord* 2004;5:7. DOI: 10.1186/1471-2474-5-7.
- Kanematsu M, Ikeda K, Yamada Y. Interaction between nitric oxide synthase and cyclooxygenase pathways in osteoblastic MC3T3-E1 cells. *J Bone Miner Res* 1997;12(11):1789–1796. DOI: 10.1359/jbmr.1997.12.11.1789.
- Salvemini D, Kim SF, Mollace V. Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications. *Am J Physiol Regul Integr Comp Physiol* 2013;304(7):R473–R487. DOI: 10.1152/ajpregu.00355.2012.
- Sakuma Y, Li Z, Pilbeam CC, et al. Stimulation of cAMP production and cyclooxygenase-2 by prostaglandin E₂ and selective prostaglandin receptor agonists in murine osteoblastic cells. *Bone* 2004;34(5):827–834. DOI: 10.1016/j.bone.2003.12.007.
- Tozum TF, Turkyilmaz I, Yamalyk N, et al. The effect of delayed versus early loading on nitric oxide metabolism around dental implants: an 18-month comparative follow-up study. *Int J Oral Maxillofac Implants* 2007;22(1):53–62.
- Alkan EA, Tüter G, Parlak A, et al. Evaluation of peri-implant crevicular fluid prostaglandin E₂ levels in augmented extraction sockets by different biomaterials. *Acta Odontol Scand* 2016;74(7):532–538. DOI: 10.1080/00016357.2016.1214979.
- Yağcı S, Baseğmez C, Mijiritsky E, et al. Detection of implant crevicular fluid prostaglandin E₂ levels for the assessment of peri-implant health: a pilot study. *Implant Dent* 2005;14(2):194–200. DOI: 10.1097/01.id.0000165027.30821.90.